PHARMAZEUTISCHE FORMULIERUNG

European patent · EP3601277 · In force

Register entry

Publication number
EP3601277
Application number
EP18715593
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 28, 2018
Published
Feb 5, 2020
Granted
Oct 11, 2023
Protection ends at the latest
Mar 27, 2038
Next annual fee due
Mar 31, 2027
IPC classes
C07D 413/14 (2006.01)
A61K 9/14 (2006.01)
A61K 9/20 (2006.01)
A61P 35/00 (2006.01)
Priority
EP 17163830 30.03.2017
PCT application
PCT/EP2018/057877 28.03.2018
PCT publication
WO2018/178134 04.10.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 1, 2026

    Change

    Published in Swissreg on 01.04.2026

  2. Apr 1, 2025

    Change

    Published in Swissreg on 01.04.2025

  3. Aug 21, 2024

    Change

    Published in Swissreg on 21.08.2024

  4. Apr 1, 2024

    Change

    Published in Swissreg on 01.04.2024

  5. Oct 11, 2023

    Granted

    Published in Swissreg on 11.10.2023

Parties

Holder

Merck Patent GmbH

Frankfurter Strasse 250, 64293 Darmstadt, DE

Inventor

BONIFORTE, Patrizia

64665 Alsbach-Haehnlein, DE

GEISSLER, Simon

61352 Bad Homburg, DE

WEIGANDT, Markus

68259 Mannheim, DE

JESCHKE, Martina

64846 Gross-Zimmern, DE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.